Anhydroglucitol

Test Name: 1,5 Anhydroglucitol Quantitative

 

Sample Type: Serum or Plasma

 

Purpose: Monitor postprandial hyperglycemia and short-term glycemic control when hemoglobin A1c is 6.1-7.9%.

 

Clinical Utility:

The quantitative measurement of 1,5 Anhydroglucitol (1,5-AG) in serum or plasma is utilized to monitor postprandial hyperglycemia and short-term glycemic control, particularly in individuals with hemoglobin A1c (HbA1c) levels ranging from 6.1% to 7.9%. 1,5-AG is a marker of glycemic excursions, providing insights into recent glycemic fluctuations, especially after meals. This test can be valuable in assessing glycemic control in diabetic patients, complementing HbA1c measurements.

 

Recommended Usage:

This test is recommended for individuals with HbA1c levels between 6.1% and 7.9% to monitor postprandial hyperglycemia and short-term glycemic control.

 

Sample Collection:

Collect serum or plasma sample according to standard protocols for blood collection.

 

Methodology:

Quantitative measurement of 1,5-AG is typically performed using enzymatic assays or other validated analytical methods.

 

Interpretation:

 

Elevated levels of 1,5-AG suggest adequate glycemic control and lower risk of postprandial hyperglycemia.

Decreased levels of 1,5-AG may indicate increased postprandial hyperglycemia and poorer short-term glycemic control.

Limitations:

 

Interpretation of 1,5-AG levels should consider factors such as renal function, medications affecting glucose metabolism, and timing of sample collection concerning meals.

Elevated levels of 1,5-AG can be influenced by factors like renal dysfunction, high-dose vitamin C supplementation, or medications such as dapagliflozin.

References:

 

Yamanouchi T, Akanuma H, Nakamura T, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet. 1996;347(9014):1514-1518.

https://www.sciencedirect.com/science/article/abs/pii/S0140673696906728

Selvin E, Rawlings AM, Grams M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2(4):279-288.

https://pubmed.ncbi.nlm.nih.gov/24703046/

This test should be interpreted in conjunction with clinical evaluation and other laboratory findings. Always consult healthcare professionals for appropriate interpretation and management decisions.